After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate

American Journal of Cardiology

Volumn 102, Issue 12 SUPPL., 2008, Pages 34L-40L

  Sacks, Frank M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO;

ALBUMINURIA; ARTICLE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK REDUCTION;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; PPAR ALPHA; PRIMARY PREVENTION; RISK; RISK ASSESSMENT;

EID: 57649104652     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.073     Document Type: Article

References (34)

1. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glosziou P., et al., FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD trial): randomised controlled trial. Lancet 366 (2005) 1849-1861
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
3. Sacks F.M., Tonkin A.M., Shepherd J., Braunwald E., Cobbe S., Hawkins C.M., Keech A., Packard C., Simes J., Byington R., and Furberg C.D. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102 (2000) 1893-1900
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
5. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H., and CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
6. Scott R., Best J., Forder P., Taskinen M.R., Simes J., Barter P., Keech A., and FIELD Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol 4 (2005) 13
7. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., Fonseca V., Gerstein H.C., Grundy S., Nesto R.W., et al., American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a Scientific Statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007) 114-126
8. Scott R., d'Emden M., Best J., Drury P., Ehnholm C., Kesaniemi A., Pardy C., Tse D., Barter P., Taskinen M.R., Copt S., Keech A., and FIELD Investigators. Features of metabolic syndrome identify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. II-838. Circulation 116 (2007) Abstract 3691
9. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Mänttäri M., Heinonen O.P., and Frick M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 85 (1992) 37-45
10. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., and Manninen V. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
11. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165 (2005) 1154-1161
12. Bezafibrate Infarction Prevention Study Investigators. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bazafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
13. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., Faas F.H., and Anderson J.W. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143-3421
15. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.W., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113 (2006) 2363-2372
16. Burgess D., Hunt D., Li L.P., Zhang J., Sy R., Laakso M., Davis T., Colman P., Forder P., Williamson E., Pike R., Keech A., and FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [abstract]. Circulation 116 (2007) II-838
17. Donahoe S.M., Stewart G.C., McCabe C.H., Mohanavelu S., Murphy S.A., Cannon C.P., and Antman E.M. Diabetes and mortality following acute coronary syndromes. JAMA 298 (2007) 765-775
18. National Diabetes Statistics. diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm Accessed March 28, 2007
19. Center for Disease Control. Lower extremity disease among persons aged ≥40 years with and without diabetes - United States, 1999-2002. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5445a4.htm Accessed June 29, 2006
20. Diabetes atlas. www.eatlas.idf.org/prevalence Accessed June 17, 2007.
21. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., Taskinen M.R., Simes R.J., Tse D., Williamson E., et al., FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
22. Harrold B.P., Marmion V.J., and Gough K.R. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 18 (1969) 285-291
23. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DIAS). Am J Kidney Dis 45 (2005) 485-493
24. Steiner G. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Am J Cardiol suppl (2008) 28L-33L
25. Kim J., Ahn J.H., Kim J.H., Yu Y.S., Kim H.S., Ha J., Shinn S.H., and Oh Y.S. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 84 (2007) 886-893
26. Keating G.M., and Croom K.F. Fenofibrate: a review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67 (2007) 121-153
27. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 suppl (2007) 3C-18C
28. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
29. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
30. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., and Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
31. Corsini A., Bellosta S., and Davidson M.H. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 96 suppl (2005) 44K-49K
32. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 suppl 1 (2008) S12-S54
33. Carrington M., and Stewart S. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes?. An economic analysis of the FIELD study. Int J Cardiol 127 (2008) 51-56
34. Buse J.B., Bigger J.T., Byington R.P., and ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes trial: design and methods. Am J Cardiol 99 suppl (2007) 21i-33i